Why is everyone selling ?, page-18

If the results come through towards the end of the six weeks then shortly after a progress report will be issued regarding the growth in Travelan sales which will hopefully build on the previous quarters 66% growth.

Travelan potential for sales growth is set out at page 21 of the recent slide updatehttps://commsec.api.markitondemand.com/commsec-node-api/1.0/event/document/1410-02096751-0SVLEDN05JA1HSB5VPDU5JBAE0/pdf?access_token=k2wCLGGSvy7E7XYfQETmbatzrcbs and it is worthwhile taking some time to consider that in 2013 two of the four known competitors Pepto Bismal and Immodium had combined sales in Travelan's targeted market of $165,100,000 US. Neither of these products actually kill/cure/remove the cause of diarrhea unlike Travelan.

The market for Travelan is huge in the order of $100,000,000 US according to Immuron once FDA approval is granted. Remember Travelan will be the first ever approved FDA drug for Travellers' Diarrhea.

Obtaining FDA approval would seem to be a given. If evidence existed that Travelan does not work or is injurious to health in some fashion it is highly likely that it would have surfaced by now.

Over 600,000 packets of Travelan have been sold and consumed and large scale testing of IMM-124E (which the company now clearly states is Travelan) has been undertaken including on human subjects in Phase 2 NASH trials and on primates by the US military.

There can be no doubt that FDA approval will eventually be forthcoming and Travelan will be the only FDA drug approved for Traveller's Diarrhea with the advantage that it will not add to antibiotic resistance and so can be prescribed without constraint by the medical profession as and when requested or when indicated.